MDWD
MediWound Ltd.
$14.21
+0.21%
$182.5M
No data for this timeframe.
Vol
Market Cap$182.5M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (92%)
Insider Activity3B / 0S
Insider Net $$29.2K
SEC Reports4
Press Releases2
Exchange Nasdaq·Sector Medicinal Chemicals & Botanical Products·Inc. L3·CIK 0001593984·Prev Close $14.18
Recent Activity
Jun 3, 2026
Insider
SHAMIR NACHUM bought 175 shares
Director @ $13.98 ($2.4K)
Jun 2, 2026
SEC
Two MediWound directors made open-market purchases totaling $27K over a 4-day window. While the dollar amount is small r
CLUSTER — Impact 4/10
Jun 1, 2026
Insider
Fox David Morton bought 1,730 shares
Director @ $14.23 ($24.6K)
May 29, 2026
Insider
Rubinstein Samuel bought 150 shares
Director @ $14.33 ($2.1K)
May 27, 2026
SEC
MediWound reported Q1 2026 revenue of $1.5M (down 63% YoY from $4.0M) and a GAAP net loss of $0.23 per share (vs. -$0.07
PRESS-RELEASE — Impact 6/10
May 27, 2026
earnings
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><em>EscharEx</em><sup><em>®</em></sup><em> Phase III VALUE trial advancing; interi
May 7, 2026
SEC
MediWound announced it will release Q1 2026 financial results on May 27, 2026, with a conference call to follow. No fina
PRESS-RELEASE — Impact 2/10
Mar 5, 2026
Press
MediWound Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, disclosing audited fina
Impact 3/10
Price Targets
$30.17
+111.0% upside
Strong Buy
Current $14.30
Low $22.00
Median $31.00
High $36.00
6 analysts
$22.00
$36.00
Analyst Ratings
3Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| May 28, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.77 ▼ -5.8% | $-0.91 — $-0.68 | 37% YoY | 5 |
| Next Q | $-0.71 ▲ +6.1% | $-0.87 — $-0.49 | -194% YoY | 5 |
| Current FY | $-2.38 ▲ +17.2% | $-2.78 — $-2.01 | -14% YoY | 4 |
| Next FY | $-2.22 ▼ -2.3% | $-2.61 — $-2.09 | 7% YoY | 5 |
Latest Reports
BULLISH
CLUSTER
4/10
Two MediWound directors made open-market purchases totaling $27K over a 4-day window. While the dollar amount is small r
Jun 2, 2026
BEARISH
PRESS-RELEASE
6/10
MediWound reported Q1 2026 revenue of $1.5M (down 63% YoY from $4.0M) and a GAAP net loss of $0.23 per share (vs. -$0.07
May 27, 2026
NEUTRAL
Press
3/10
MediWound Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, disclosing audited fina
Mar 5, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | SHAMIR NACHUM | BUY | $2.4K |
| Jun 1, 2026 | Fox David | BUY | $24.6K |
| May 29, 2026 | Rubinstein Samuel | BUY | $2.1K |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
3 unique insiders with 3 transactions. Net insider value: $29.2K ($29.2K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | SHAMIR NACHUM | Director | BUY | 175 | $13.98 | $2.4K |
| Jun 1, 2026 | Fox David Morton | Director | BUY | 1,730 | $14.23 | $24.6K |
| May 29, 2026 | Rubinstein Samuel | Director | BUY | 150 | $14.33 | $2.1K |
4 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 3.5/10.
BULLISH
CLUSTER
4/10
Two MediWound directors made open-market purchases totaling $27K over a 4-day window. While the doll
Jun 2, 2026
BEARISH
PRESS-RELEASE
6/10
MediWound reported Q1 2026 revenue of $1.5M (down 63% YoY from $4.0M) and a GAAP net loss of $0.23 p
May 27, 2026
NEUTRAL
PRESS-RELEASE
2/10
MediWound announced it will release Q1 2026 financial results on May 27, 2026, with a conference cal
May 7, 2026
NEUTRAL
6-K
2/10
MediWound Ltd. (MDWD) has issued a 6-K filing to announce its 2026 Annual General Meeting of Shareho
Mar 30, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 3 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$30.17 mean target
+111.0% upside
Strong Buy (1.17)
$22.00 Low
$36.00 High
| Metric | Value |
|---|---|
| Current Price | $14.30 |
| Target Low | $22.00 |
| Target Mean | $30.17 |
| Target Median | $31.00 |
| Target High | $36.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.17) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.77 | $-0.91 | $-0.68 | 37.4% | -5.8% | 1↑ 2↓ | $0.0B | -54.6% | 5 |
| Next Q 2026-09-30 |
$-0.71 | $-0.87 | $-0.49 | -194.2% | +6.1% | 4↑ 1↓ | $0.0B | 60.2% | 5 |
| Current FY 2026-12-31 |
$-2.38 | $-2.78 | $-2.01 | -13.6% | +17.2% | 4↑ 0↓ | $0.0B | 42.3% | 4 |
| Next FY 2027-12-31 |
$-2.22 | $-2.61 | $-2.09 | 6.9% | -2.3% | 2↑ 3↓ | $0.0B | 36.3% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.770 | |
| 7d ago | $-0.728 | -0.042 |
| 30d ago | $-0.728 | -0.042 |
| 60d ago | $-0.728 | -0.042 |
| 90d ago | $-0.593 | -0.177 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| May 28, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
May 27, 2026
earnings
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><em>EscharEx</em><sup><em>®</em></sup><em> Phase III VALUE trial advancing; interim assessment and enrollment completion expected </
May 27, 2026
earnings_calendar
MDWD Q1 2026 Earnings Scheduled — 2026-05-27
May 8, 2026
short_interest
FTD: MDWD — 93,972 shares ($1.6M) failed to deliver
Settlement: 20260508, Price: $17.27, FTD Value: $1,622,896.44, MEDIWOUND LTD ORD SHS NEW
May 7, 2026
earnings
MediWound to Report First Quarter 2026 Financial Results
<p align="center"><b>MediWound to Report First Quarter 2026 Financial Results </b></p>
Apr 13, 2026
other
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
<p align="center"><b>Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement</b></p>
Apr 7, 2026
other
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
<p align="center"><b>MediWound to Present New EscharEx</b><sup><b>®</b></sup><b> Data at Leading Wound Care Conferences</b> </p>
Apr 2, 2026
contract
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
<p align="center"><b>MediWound Reports BARDA Contract Award to Vericel for NexoBrid</b><sup><b>®</b></sup><b> Valued at up to $197 Million</b></p>
Mar 5, 2026
earnings
MediWound Files Annual Report on Form 20-F
<p align="center"><span><b>MediWound Files Annual Report on Form 20-F </b></span></p>
Mar 5, 2026
earnings
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
<p align="center"><em>EscharEx</em><sup><em>®</em></sup><em> Phase III VALUE trial advancing as planned</em></p>
Mar 5, 2026
earnings_calendar
MDWD Q4 2025 Earnings After Market Close — 2026-03-05